Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice

Nephrology Dialysis Transplantation

Volumn 26, Issue 4, 2011, Pages 1194-1204

  Kang, Young Sun ^a   Lee, Mi Hwa ^a   Song, Hye Kyoung ^a   Hyun, Young Youl ^a   Cha, Jin Joo ^a   Ko, Gang Jee ^a   Kim, Sung Hwan ^a   Lee, Ji Eun ^b   Han, Jee Young ^c   Cha, Dae Ryong ^a  

^a Korea University   (South Korea)

^b Wonkwang University   (South Korea)

^c Inha University   (South Korea)

Author keywords

aliskiren; diabetic complication; direct renin inhibitor; insulin resistance

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOKINE PRODUCTION; DIABETIC ANGIOPATHY; DRUG EFFICACY; ELECTROLYTE BLOOD LEVEL; GENE EXPRESSION; GLOMERULOSCLEROSIS; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE;

AMIDES; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; BLOTTING, WESTERN; BODY WEIGHT; CELLS, CULTURED; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FUMARATES; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; INSULIN; INSULIN RESISTANCE; MALE; MESANGIAL CELLS; MICE; MICE, MUTANT STRAINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RENIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 79953886761     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq579     Document Type: Article

References (40)

1. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116: 288-296 (Pubitemid 43228342)
2. Ingelfinger JR. Aliskiren and dual therapy in type 2 diabetes mellitus. N Engl J Med 2008; 358: 2503-2505 (Pubitemid 351793025)
3. Price DA, Porter LE, Gordon M et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999; 10: 2382-2391 (Pubitemid 29501472)
4. Skeggs LT Jr, Kahn JR, Lentz K et al. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957; 106: 439-453
5. Cohen NC. Structure-based drug design and the discovery of aliski-ren (Tekturna): perseverance and creativity to overcome a R&D pipeline challenge. Chem Biol Drug Des 2007; 70: 557-565
6. Villamil A, Chrysant SG, Calhoun D et al. Renin inhibition with alis-kiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25: 217-226 (Pubitemid 44885684)
7. Stanton A, Jensen C, Nussberger J et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: 1137-1143 (Pubitemid 37549068)
8. Oparil S, Yarows SA, Patel S et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370: 221-229 (Pubitemid 47069535)
9. Pilz B, Shagdarsuren E, Wellner M et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005; 46: 569-576 (Pubitemid 41376839)
10. Kelly DJ, Zhang Y, Moe G et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007; 50: 2398-2404 (Pubitemid 47512400)
11. Dahlof B, Devereux RB, Kjeldsen SE et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003 (Pubitemid 34286536)
12. Kjeldsen SE, Julius S, Mancia G et al. VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2006; 24: 1405-1412 (Pubitemid 43948341)
13. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. Meta-analysis of randomized clinical trials. Diab Metab 2004; 30: 487-496 (Pubitemid 40070350)
14. Lua T, Carlsson PO, Leung PS. Evidence of a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabe-tologia 2004; 47: 240-248 (Pubitemid 38315360)
15. Chu KY, Lau T, Carlsson PO et al. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 2006; 55: 367-374 (Pubitemid 43343265)
16. Furuhashi M, Ura N, Higashiura K et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81 (Pubitemid 36842239)
17. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003; 14: 281-287 (Pubitemid 36688207)
18. Francis GA, Annicotte JS, Auwerx J. PPAR-alpha effects on the heart and other vascular tissues. Am J Physiol Heart Circ Physiol 2003; 285: H1-H9 (Pubitemid 36736408)
19. Park CW, Kim HW, Ko SH et al. Long-term treatment of gluca-gon-like peptide-1 analog exendin-4 ameliorates diabetic nephro-pathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007; 18: 1227-1238 (Pubitemid 46536909)
20. Proctor G, Jiang T, Iwahashi M et al. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 2006; 55: 2502-2509 (Pubitemid 44871150)
21. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-917
22. Han SY, Kim CH, Kim HS et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006; 17: 1362-1372
23. O'Brien E, Barton J, Nussberger J et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007; 49: 276-284 (Pubitemid 46143002)
24. Parving HH, Persson F, Lewis JB et al. Aliskiren combined with lo-sartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446 (Pubitemid 351793017)
25. Hauner H, Rohrig K, Spelleken M et al. Development of insulin-responsive glucose uptake and GLUT4 expression in differentiating human adipocyte precursor cells. Int J Obes Relat Metab Disord 1998; 22: 448-453 (Pubitemid 28211973)
26. Marin P, Andersson B, Ottosson M et al. The morphology and metabolism of intraabdominal adipose tissue in men. Metabolism 1992; 41: 1242-1248
27. Diamanti-Kandarakis E, Economou FN, Livadas S et al. Hyperre-ninemia characterizing women with polycystic ovary syndrome improves after metformin therapy. Kidney Blood Press Res 2009; 32: 24-31
28. Takahashi N, Li F, Hua K et al. Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. Cell Metab 2007; 6: 506-512 (Pubitemid 350163052)
29. Habibi J, Whaley-Connell A, Hayden MR et al. Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology 2008; 149: 5643-5653
30. Lastra G, Habibi J, Whaley-Connell AT et al. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 2009; 150: 2561-2568
31. Barlucchi L, Leri A, Dostal DE et al. Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure. Circ Res 2001; 88: 298-304 (Pubitemid 32173753)
32. Xiang W, Kong J, Chen S et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: E125-E132 (Pubitemid 40023798)
33. Singh VP, Baker KM, Kumar R. Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. Am J Physiol Heart Circ Physiol 2008; 294: H1675-H1684 (Pubitemid 351490598)
34. Vidotti DB, Casarini DE, Cristovam PC et al. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol 2004; 286: F1039-F1045 (Pubitemid 38656357)
35. Leite CA, Cristovam PC, LeitaoAA et al. Renin similar to the submax-illary gland form is expressed in mouse mesangial cells: subcellular localization and all generation under control and glucose-stimulated conditions. Cell Physiol Biochem 2003; 13: 357-366 (Pubitemid 37465151)
36. Cha DR, Kang YS, Han SY et al. Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats. J Endocrinol 2004; 183: 183-194 (Pubitemid 40124655)
37. Shi RZ, Wang JC, Huang SH et al. Angiotensin II induces vascular endothelial growth factor synthesis in mesenchymal stem cells. Exp Cell Res 2009; 315: 10-15
38. Gruden G, Thomas S, Burt D et al. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J Am Soc Nephrol 1999; 10: 730-737 (Pubitemid 29149522)
39. Satofuka S, Ichihara A, Nagai N et al. (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes 2009; 58: 1625-1633
40. Advani A, Kelly DJ, Advani SL et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci USA 2007; 104: 14448-14453 (Pubitemid 350003281)